Yingke Biopharmaceutical has raised 300 million yuan ($42.4 million) in a Series B round led by Hong Kong-listed China Life Insurance’s private equity arm as it looks to expand its operations across the country.
Continue reading this premium story with a subscription to DealStreetAsia.Subscribe
Already a Subscriber? Log in
Contact us for corporate subscriptions at firstname.lastname@example.org